Silencing ACSL4 inhibited sorafenib-induced lipid peroxidation and ferroptotic cell death in HCC cells, indicating that ACSL4 may be a potential predictive biomarker of HCC. This evidence concerns the gene ACSL4 and hepatocellular carcinoma.